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This background document has been prepared by the Strategic Advisory Group of Experts (SAGE) on 
Immunization Working Group on COVID-19 Vaccines to inform the discussions of SAGE at its 5 January 2021 
extraordinary meeting [1], which resulted in the issuance of the 8 January 2021 WHO Interim recommendations 
for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing 
(https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-
2021.1, accessed 11 January 2021).  
Declarations of interests were collected from all external contributors and assessed for any conflicts of interest. 
Summaries of the reported interests can be found on the SAGE meeting website and SAGE Working Group 
website. 
 
General considerations on mRNA vaccines 
The advantages of RNA-based vaccines are that they can be developed rapidly. mRNA-based vaccines avoid the 
risk of integration with the host cell genome and are able to produce pure viral protein. mRNA is transiently 
expressed, allowing protein to be made within the cell. Lipid nanoparticle (LNP)-formulated mRNA vaccine 
technology allows precise genetic information to be delivered, together with an adjuvant effect, to antigen-
presenting cells. It is molecularly well defined, free from materials of animal origin, and synthesized by an 
efficient, cell-free in vitro transcription process from DNA templates. The technology associated with this 
vaccine is also capable of bypassing time-consuming standardization processes, allowing speedy commercial 
production. The fast and highly scalable mRNA manufacturing and LNP formulation processes allow rapid 
production of many vaccine doses, which is particularly important during a pandemic. 
 
Characteristics of COVID-19 vaccine BNT162b2 (Pfizer–BioNTech)  
The Pfizer–BioNTech COVID-19 vaccine, BNT162b2, is an mRNA vaccine encoding a P2 mutant spike 
protein (PS 2) and formulated as an RNA–lipid nanoparticle of nucleoside-modified mRNA (modRNA). 
BNT162b2 elicits a blunted innate immune sensor activating capacity and thus augments antigen expression. 
Encapsulation into LNPs allows transfection of the mRNA into host cells after intramuscular (IM) injection. 
During mixing of the RNA and the dissolved lipids, the lipids form the nanoparticles encapsulating the RNA. 
After injection, the LNPs are taken up by the cells, and the RNA is released into the cytosol, where it is 
translated into the encoded viral protein. The mRNA is rapidly degraded intracellularly, while the resulting 
peptides are presented at the cell surface, triggering a specific humoral T-cell-mediated immune response with 
activity against the spike protein.  
 
Development process, contents, formulation 
BNT162b2 is produced as a highly purified single-stranded, 5`-capped mRNA; the mRNA encodes the viral 
spike from SARS-CoV-2. The following excipients are included: ALC-0315, ALC-0159 (polyethylene glycol), 
cholesterol, potassium chloride, potassium dihydrogen phosphate, sodium chloride, disodium hydrogen 
phosphate dihydrate, sucrose, and water for injection.  
 
Preclinical studies 
A single injection of BNT162b2 elicited high neutralizing antibody titres in mice. Vaccination of mice also 
resulted in robust T helper 1 (TH1) and T follicular helper (TFH) type CD4+ responses as well as a robust 
IFNγ+IL-2+ CD8+ T-cell response. This pattern of cell-mediated immunity suggests a low likelihood that the 
vaccine will induce a hypersensitivity response and resulting vaccine-associated enhanced respiratory disease. 
In addition, the induction of a TFH response supports the hypothesis that the vaccine may confer durable 
immunity. Translation of this immunogenicity profile into protection against subsequent viral infection was 
tested in a non-human primate (NHP) study.  
The immunogenicity of BNT162b2 in rhesus macaques paralleled that observed in the murine model (1). Two 
doses of 100 μg of this mRNA vaccine were given at 0 and 21 days. Seven days after the second dose, the 50% 
virus neutralization titre of antibodies reached 18 times that of a human SARS-CoV-2 convalescent serum 
panel; it remained 3.3 times higher than this benchmark five weeks after the second immunization, although the 
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absolute titre decayed from 1689 to 310. The TH1-based CD4+ response and the IFNγ+ CD8+ T-cell response 
mirrored the cellular immunogenicity profile reported in mice. Two doses of 100 μg of BNT162b2, separated by 
a three-week interval, protected 2–4-year-old rhesus macaques against viral infection when challenged, 
intranasally and intratracheally, with 1x106 plaque-forming units (pfu) of SARS-CoV-2 55 days after the second 
vaccination. Viral RNA, as measured by reverse transcription quantitative polymerase chain reaction (RT-
qPCR), in the bronchoalveolar lavage fluid (BAL) and nasopharyngeal (NP) and oropharyngeal (OP) swabs, 
was significantly lower in the vaccinated animals than in the unvaccinated controls. The virus was absent on day 
3 and day 6 after challenge. No measurements were made at other times. Histopathological outcomes were not 
presented in any detail in this NHP study; protective efficacy was limited to virological outcomes. Overall, these 
preclinical data indicate that BNT162b2 is an immunogenic vaccine that is efficacious in protecting against viral 
infection in the lower and upper airways of rhesus macaques three days after challenge. 
 
Clinical studies: phases 1 and 2 
Safety 
Two candidate mRNA vaccines were tested in phase 1 trials: BNT162b1 and BNT162b2. The latter was 
ultimately advanced to phase 3 trials because it was better tolerated and represented a greater breadth of T-cell 
epitopes (2). Overall, the vaccine, given as a two-dose regimen at one of three doses (10 μg, 20 μg, 30 μg) was 
tolerated well in two age groups: 18–55 years and 65–85 years. Local and systemic adverse events were 
generally mild and were more frequent in the two higher dose groups. Systemic adverse events were generally 
milder in the older age group. Perturbations in laboratory values that were deemed related to vaccine 




Neutralizing antibody titres (50% neutralizing geometric mean titres (GMTs)) elicited by BNT162b2 peaked 
one week after the second vaccination and began decaying one week after that. There was a trend towards 
higher titres in individuals who had received the highest vaccine dose of 30 μg. Vaccination with this dose 
elicited titres that were lower than those seen in animal studies; titres were 1.7–4.6 times higher than that seen in 
a convalescent serum panel among the 18–55-year-olds and 1.1–2.2 times higher among the 65–85-year-olds. 
The adult population studied for safety and immunogenicity was stratified by age but skewed towards a 
Caucasian background (85%). The population in the phase 3 trial assessing efficacy of BNT162b2 was more 
diversified. 
 
Clinical studies: phase 2/3 trials (3) 
Efficacy 
Trial population 
The phase 2/3 pivotal registration trial of the vaccine was conducted at sites in six countries (Argentina, Brazil, 
Germany, South Africa, Turkey and the USA) and involved about 43 000 participants aged 16 to 85 years, who 
were healthy or had stable medical conditions, randomized equally between vaccine and placebo groups. About 
6% of participants had serological evidence of a past SARS-CoV-2 infection at entry to the trial. The vaccine 
was administered in two doses separated by 21 days, with a range of 19 to 42 days. Most participants were 
white (83%) and from sites in the USA (77%). Similar numbers of males and females were included; 42% of the 
trial population was aged over 55 years, and 22% over 64 years, with a median age at vaccination of 52 years. 
About 46% of participants were obese or had a co-morbid condition that was likely to increase their risk of 
severe COVID-19. The primary analysis of the trial results was conducted when participants had been followed 
for an average of two months after the second vaccine dose; 92% had been followed for at least one month after 
the second dose. 
 
Efficacy against COVID-19 
Two primary endpoints were specified: efficacy among all participants and efficacy among participants who had 
no evidence of a previous SARS-CoV-2 infection 7 days after the second vaccine dose. The primary assessment 
of efficacy was based on the 178 cases of symptomatic laboratory-confirmed SARS-CoV-2 infection that 
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occurred between 7 days after the second vaccine dose and the end of the follow-up period. Of these cases, 9 
were in the vaccinated group and 169 in the placebo group, giving an estimated vaccine efficacy (VE) of 94.6% 
(95% credibility interval (CI) 89.9–97.3%). When analysis was confined to participants without evidence of a 
previous SARS-CoV-2 infection, the case numbers were 8 in the vaccine group and 162 in the placebo group, 
with an estimated VE of 95.0% (95% CI 90.3–97.6%).  
Analyses were also conducted including all cases from the time of the first dose. There was evidence of 
protection both between the first and second doses (VE 52.4%, 95% CI 29.5–68.4%) and between the second 
dose and 7 days after the second dose (VE 90.5%, 95% CI 61.05–98.9%). More detailed analyses indicated that 
there was no evidence of protection until about 12 days after the first dose, but subsequently the incidence of 
COVID-19 was lower among vaccinated participants.  
For the period starting 7 days after the second vaccination, no significant variations in the estimates of vaccine 
efficacy were apparent when the primary analyses were stratified according to sex, age, race, ethnicity, country, 
comorbid conditions or obesity, and obesity alone. In particular, among those aged 65 years or older, without 
evidence of prior infection up to 7 days after the second dose, there was 1 case in the vaccinated group and 19 
cases in the placebo group (VE 94.7%, 95% CI 66.7–99.9%). 
 
Efficacy against severe COVID-19 
A total of 10 cases of severe COVID-19 occurred in trial participants, 1 in the vaccinated group and 9 in the 
placebo group (VE 88.9%, 95% CI 20.1–99.7%). Of these cases, 5 occurred 7 or more days after the second 
vaccine dose, 1 in the vaccine group and 4 in the placebo group (VE 75%, 95% CI –152.6–99.5%).  
 
Summary of efficacy evidence in phase 2/3 trials  
The vaccine was highly efficacious against laboratory-confirmed COVID-19 from 7 days after the second 
vaccine dose until the end of the follow-up period, which was, on average, 2 months. Evidence of efficacy 
emerged from about 12 days after the first vaccine dose. No evidence of variations in efficacy were found in the 
various subgroups that were analyzed. Importantly, in subgroups likely to be at higher risk of severe COVID-19, 
including those aged over 65 years and those with comorbid conditions or obesity, the estimates of efficacy 
were very high. Few participants in the trial developed severe COVID-19, so efficacy against this endpoint is 
less certain, but from the time of the first dose, there was only 1 severe case in the vaccinated group and 9 in the 
placebo group, consistent with high efficacy. 
 
Vaccine safety 
Safety data from 37 586 participants ≥16 years of age randomized 1:1 to vaccine or placebo with a median of 2 
months of follow-up after the second dose suggested a favourable safety profile. Reactogenicity symptoms, 
defined as solicited local injection site or systemic reactions during the seven days after vaccination, were 
frequent and mostly mild to moderate. Reactogenicity and adverse events (AEs) were generally milder and less 
frequent in the older group (≥55 years of age) than the younger group (18–55 years of age) and tended to be 
more frequent and severe after the second dose. Reactogenicity was mostly mild to moderate and short-lived for 
both age groups (median onset was 0–2 days after either dose for a median duration of 1–2 days). The vaccine’s 
AE profile did not suggest any specific safety concerns. The median onset of systemic AEs was 1–2 days after 
either dose for a median duration of 1 day. Severe adverse reactions occurred in 0.0–4.6% of participants. The 
incidence rates of serious adverse events (SAEs), deaths, and discontinuation due to AEs were low and 
comparable for the vaccine and placebo groups. No specific safety concerns were identified in subgroup 
analyses by age, race, ethnicity, medical comorbidities, or prior SARS-CoV-2 infection. 
 
Adverse events 
The most common solicited adverse reactions in participants 16 years of age and older included pain at the 
injection site (84.1%), fatigue (62.9%), headache (55.1%), muscle pain (38.3%), chills (31.9%), joint pain 
(23.6%), fever (14.2%), injection site swelling (10.5%), injection site redness (9.5%), nausea (1.1%), malaise 
(0.5%), and lymphadenopathy (0.3%). The mean duration of pain at the injection site after dose 2 was 2.5 days 
(range 1 to 36 days), redness 2.6 days (range 1 to 34 days), and swelling 2.3 days (range 1 to 34 days).  
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Adverse events of special interest, that would potentially require longer follow up  
Lymphadenopathy 
Lymphadenopathy was reported in 64 participants (0.3%). There were more cases in the vaccine group (64) than 
the placebo group (6). In the vaccine group, 54 (0.5%) occurred in the younger age group (16–55 years) and 10 
(0.1%) in the older age group (>55 years). Lymphadenopathy occurred in the arm and neck region, and was 
reported within 2–4 days after vaccination. The average duration of these events was approximately 10 days, 
with 11 events ongoing at the time of the data cut-off. 
 
Bell’s palsy 
Bell’s palsy was reported by four participants in the vaccine group and none in the placebo group. These cases 
occurred at 3, 9, 37, and 48 days after vaccination. One case (onset at 3 days post-vaccination) was reported as 
resolved with sequelae within three days of onset, and the other three were reported as continuing or resolving 
as of the 14 November 2020 data cut-off, with ongoing durations of 10, 15, and 21 days, respectively. The usual 
incidence of Bell`s palsy is 15–30 per 100 000 per year (4). The observed frequency of reported Bell’s palsy in 
the vaccine group is consistent with the expected background rate in the general population. An association 
between COVID-19 and Bell’s palsy has been reported. At this point in time, there is no clear basis upon which 
to conclude a causal relationship, but surveillance for cases of Bell’s palsy with deployment of the vaccine into 
larger populations is an absolute requirement. Bell`s palsy has been addressed in the risk management plan.  
 
Allergic reactions 
The Food and Drug Administration of the USA independently conducted standard MedDRA queries (SMQs) on 
the phase 2/3 all-enrolled safety population using FDA-developed software. This was to evaluate for 
constellations of unsolicited adverse event preferred terms that could represent various diseases and conditions, 
including allergic, neurological, inflammatory, and autoimmune conditions. The SMQs revealed a slight 
numerical imbalance of adverse events potentially representing allergic reactions, with more participants 
reporting hypersensitivity-related adverse events in the vaccine group (137, 0.63%) compared with the placebo 
group (111, 0.51%). No imbalances between treatment groups were evident for any of the other SMQs 
evaluated (5). 
Severe allergic reactions have been reported following administration of the Pfizer–BioNTech COVID-19 
vaccine during mass vaccination outside of clinical trials. Severe allergic reactions to any ingredient of this 
vaccine, or a previous dose of this vaccine, are a contraindication.  
Additional adverse reactions may become apparent with more widespread use of the Pfizer–BioNTech COVID-
19 vaccine. 
 
Serious adverse events  
Two of the SAEs considered as possibly related to the vaccine were shoulder injury possibly related to vaccine 
administration or to the vaccine itself, and lymphadenopathy involving the axilla ipsilateral to the vaccine 




Across both treatment groups, 20.5% of participants had a comorbidity (as per the Charlson Comorbidity 
Index). The most frequently reported comorbidities were diabetes, with or without chronic complications (8.4%) 
and pulmonary disease (7.8%), which were reported at similar frequencies in each group. More participants had 
comorbidities in the older population (31.1%) than the younger population (12.8%), including diabetes (14.6% 
and 3.8%), malignancy (7.4% and 1.0%), and pulmonary disease (8.8% and 7%).  
Overall, 0.3% of participants were HIV-positive and were evenly distributed between treatment groups. The 
HIV-positive participants were included in the safety population and are shown as part of the study 
demographics and disposition, but their safety data were not available to contribute to the safety analyses at the 
time of the data cut-off.  
 




Female study participants with childbearing potential were screened for pregnancy prior to each vaccination. 
Anyone who tested positive was excluded or discontinued from the study. The study is collecting data on 
outcomes of all reported pregnancies that occurred either after vaccination or before vaccination but without 
being detected by prevaccination screening tests. Twenty-three such pregnancies were reported up to the data 
cut-off date of 14 November 2020 (12 in the vaccine group, 11 in the placebo group). Pregnancy outcomes are 
currently not known. Available data on the BNT162b2 vaccine administered to pregnant women are insufficient 
to allow assessment of vaccine-associated risks in pregnancy. 
 
Special considerations 
PEGylation (or pegylation) 
The Pfizer BioNTech BNT162b2 vaccine contains four lipids. The lipids encapsulate the mRNA in the form of 
a lipid nanoparticle to aid cell entry and stability of the RNA/lipid nanoparticles. The four lipids are: 
• cholesterol  
• 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)  
• ALC-0315 ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate)) 
• ALC-0159 (2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide). 
Two of the lipids are commonly used in approved medicinal products (cholesterol and 1,2-distearoyl-sn-
glycero-3-phosphocholine (DSPC)). ALC-0159 is a polyethylene glycol (PEG) lipid conjugate (i.e. PEGylated 
lipid). The primary function of the PEGylated lipid ALC-0159 is to form a protective hydrophilic layer that 




Of the excipients, ALC-0159 has the ability to cause allergic reactions, since it contains polyethylene glycol or 
macrogol.  
First published data on anaphylaxis following mass roll-out in the United States after emergency use 
authorization 
During December 14–23, 2020, monitoring by the Vaccine Adverse Event Reporting System detected 21 cases 
of anaphylaxis after administration of a reported 1,893,360 first doses of the Pfizer-BioNTech COVID-19 
vaccine (11.1 cases per million doses); 71% of these occurred within 15 minutes of vaccination (6). 
 
Summary of vaccine safety aspects 
Reactogenicity and adverse events associated with the vaccine were generally milder and less frequent in the 
older group (≥55 years of age) than the younger group (18–55 years of age) and tended to increase after the 
second dose. Reactogenicity was mostly mild to moderate and short-lived for both adult age groups (median 
onset was 0–2 days after either dose for a median duration of 1–2 days). Available data on the vaccine 
administered to pregnant women are insufficient to allow assessment of vaccine-associated risks in pregnancy. 
Adverse events of special interest (that would require longer follow up) include lymphadenopathy, Bell’s palsy 
and allergic reactions.  
 
Vaccine storage 
This vaccine requires an ultra-low-temperature freezer for storage up to 6 months. Temperature-controlled 
thermal shippers using dry ice to maintain the recommended temperature of –70 °C ± 10 °C for up to 10 days 
will be needed for transportation. Each thermal shipper should have a reusable global positioning system (GPS) 
temperature-monitoring device.  
The intent is to use Pfizer strategic transportation partners to ship by air to major hubs within a country or 
region and by ground transport to dosing locations. GPS-enabled thermal sensors will be used and a control 
tower will track the location and temperature of each vaccine shipment along their pre-set routes. These GPS-
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enabled devices will allow detection of unwanted deviations. Shipment and transfer of vaccines is directed to 
“points of use” (POU).  
Once a POU receives a thermal shipper with the vaccine, there are three options for storage.  
• Ultra-low-temperature freezers, which are commercially available and can extend shelf-life for up to six 
months. 
• Refrigeration units, which are commonly available in hospitals: the vaccine can be stored for five days 
in such refrigerators at 2–8 °C. 
• The Pfizer thermal shippers in which doses arrive can be refilled with dry ice and used as temporary 
storage units for up to 15 days. After the 15 days, the vials may be transferred to refrigerated storage at 
2–8 °C for an additional five days, giving a total storage time of 20 days.  
Once thawed and stored at 2–8 °C, the vials may not be refrozen or stored in frozen condition. 
The various storage options at the POU allow equitable access to the Pfizer vaccine for areas with differing 
infrastructure. 
 
Manufacturer’s recommended dosage and schedules including boosters 
The Pfizer–BioNTech COVID-19 vaccine BNT162b2 (30 µg) is administered intramuscularly as a series of two 
30-µg doses of the diluted vaccine solution (0.3 ml each) according to the following schedule: a single dose 
followed by a second dose 21 days later. The interval between the two doses in the trial ranged from 19 to 45 
days. Studies to determine the need for, and timing of, boosters have been initiated. For the current timing, the 
schedule determines two doses only.  
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The annexes contain the grading of recommendations, assessment, development and evaluations – GRADE tables 
(Annex 1 to 6) and the SAGE evidence-to-recommendation framework tables – ETR tables (Annex 7-9). The 
ETR tables are based on the DECIDE Work Package 5: Strategies for communicating evidence to inform decisions 
about health system and public health interventions. Evidence to a recommendation (for use by a guideline panel) 
(www.decide-collaboration.eu/, accessed 11 January 2021). 
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Annex 1: GRADE table: Efficacy of BNT162b2 COVID-19 vaccine in adults 
Population: Adults (16–55 years) 
Intervention: Two doses of BNT162b2 vaccine 
Comparison: Placebo/ no vaccination 
Outcome: COVID-19 (PCR-confirmed) 
What is the efficacy of two doses of BNT162b2 vaccine compared with placebo in preventing PCR-confirmed 
COVID-19 in adults (≥16–55 years)? 
    Rating Adjustment to rating 
   















Limitation in study 
designa Not serious
b 0 
Inconsistency Not serious 0 
Indirectness Not serious 0 
Imprecision Not serious 0 




Large effect Not applicable  0 
Dose-response Not applicable  0 
Antagonistic bias 
and confounding Not applicable  0 












Statement on quality of evidence 
Evidence supports a high level of confidence that 
the true effect lies close to that of the estimate of 
the effect on the health outcome (level 4, or 
⊕⊕⊕⊕). 
Conclusion 
We are very confident that 2 doses of BNT162b2 
vaccine are efficacious in preventing PCR-
confirmed COVID-19 in adults (16–55 years). 
References: 
(1)  Pfizer-BioNtech COVID-19 vaccine (Bnt162, Pf-07302048). Vaccines and Related Biological 
Products Advisory Committee briefing document. Meeting date: 10 December 2020. Food and Drug 
Administration; 2020 (www.fda.gov/media/144246/download, accessed 10 December 2020).   
(2)  Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S et al. Safety and efficacy of the 




a For the risk of bias assessments using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), please see 
www.covid-nma.com/vaccines. 
b Data on long-term protection emerging from the ongoing phase 2/3 clinical trial remain limited, as trial data have so far 
been reported only for a follow-up of approximately 2 months. This was considered as not constituting a limitation that 
would lead to downgrading of the evidence. SAGE will continue to review any emerging data and adjust its quality 
assessment as required. 
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Annex 2: GRADE table: Safety of BNT162b2 COVID-19 vaccine in adults 
Population: Adults (16–55 years) 
Intervention: One or two doses of BNT162b2 vaccine 
Comparison: Placebo/ no vaccination 
Outcome: Serious adverse events following immunization 
What is the risk of serious adverse events following BNT162b2 vaccination compared with placebo in adults (16–
55 years)? 
    Rating Adjustment to rating 
   















Limitation in study 
designa Serious
b -1 
Inconsistency Not serious 0 
Indirectness Not serious 0 
Imprecision Not serious 0 




Large effect Not applicable  0 
Dose-response Not applicable  0 
Antagonistic bias 
and confounding Not applicable  0 












Statement on quality of evidence 
Evidence supports a moderate level of confidence 
that the true effect lies close 
to that of the estimate of the effect on the health 
outcome (level 3, or ⊕⊕⊕). 
Conclusion 
We are moderately confident that the risk of 
serious adverse events following one or two doses 
of BNT162b2 vaccine in adults (16–55 years) is 
low. 
References: 
(1)  Pfizer-BioNtech COVID-19 vaccine (Bnt162, Pf-07302048). Vaccines and Related Biological 
Products Advisory Committee briefing document. Meeting date: 10 December 2020. Food and Drug 
Administration; 2020 (www.fda.gov/media/144246/download, accessed 10 December 2020).   
(2)  Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S et al. Phase I/II study of 
COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020;586(7830):589-93. 
(3)  Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S et al. Safety and efficacy of the 
BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020: 383:2603-2615.. 
 
 
a For the risk of bias assessments using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), please see 
www.covid-nma.com/vaccines. 
b Downgraded for limitations in follow-up time of clinical trial, which may not allow detection of adverse events occurring 
several months after vaccination. Not adequately powered to detect rare adverse events. These may emerge only when large 
populations have been vaccinated.  
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Annex 3:GRADE table: Efficacy of BNT162b2 COVID-19 vaccine in older adults  
Population: Older adults (>55 years) 
Intervention: Two doses of BNT162b2 vaccine 
Comparison: Placebo/ no vaccination 
Outcome: COVID-19 (PCR-confirmed) 
What is the efficacy of two doses of BNT162b2 vaccine compared with placebo in preventing PCR-confirmed 
COVID-19 in older adults (>55years)? 
    Rating Adjustment to rating 
   















Limitation in study 
designa Not serious 0 
Inconsistency Not serious 0 
Indirectness Not seriousb 0 
Imprecision Not serious 0 




Large effect Not applicable  0 
Dose-response Not applicable  0  
Antagonistic bias 
and confounding Not applicable  0  












Statement on quality of evidence 
Evidence supports a high level of confidence that 
the true effect lies close to that of the estimate of 
the effect on the health outcome (level 4, or 
⊕⊕⊕⊕). 
Conclusion 
We are confident that 2 doses of BNT162b2 
vaccine are efficacious in preventing PCR-
confirmed COVID-19 in older adults (>55 years). 
References: 
(1)  Pfizer-BioNtech COVID-19 vaccine (Bnt162, Pf-07302048). Vaccines and Related Biological 
Products Advisory Committee briefing document. Meeting date: 10 December 2020. Food and Drug 
Administration; 2020 (www.fda.gov/media/144246/download, accessed 10 December 2020).   
(2)  Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S et al. Safety and efficacy of the 
BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020: 383:2603-2615.. 
  
 
a For the risk of bias assessments using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), please see 
www.covid-nma.com/vaccines. 
b Of the trial participants, approximately 40% were aged over 55 years. Data on long-term protection emerging from the 
ongoing phase 2/3 clinical trial remain limited, as trial data have so far been reported only for a follow-up of approximately 
2 months. This was considered as not constituting a limitation that would lead to downgrading of the evidence. SAGE will 
continue to review any emerging data and adjust its quality assessment as required. 
Background document on the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19 
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Annex 4:GRADE table: Safety of BNT162b2 COVID-19 vaccine in older adults 
Population: Older adults (>55 years) 
Intervention: One or two doses of BNT162b2 vaccine 
Comparison: Placebo/ no vaccination 
Outcome: Serious adverse events following immunization 
What is the risk of serious adverse events following BNT162b2 vaccination compared with placebo in older adults 
(>55 years)? 
    Rating Adjustment to rating 
   















Limitation in study 
designa Serious
b -1 
Inconsistency Not serious 0 
Indirectness Not serious 0 
Imprecision Not serious 0 




Large effect Not applicable  0 
Dose-response Not applicable  0  
Antagonistic bias 
and confounding Not applicable  0  












Statement on quality of evidence 
Evidence supports a moderate level of confidence 
that the true effect lies close to that of the estimate 
of the effect on the health outcome (level 3, or 
⊕⊕⊕). 
Conclusion 
We are moderately confident that the risk of 
serious adverse events following one or two doses 
of BNT162b2 vaccine in older adults (>55 years) 
is low. 
References: 
(1)  Pfizer-BioNtech COVID-19 vaccine (Bnt162, Pf-07302048). Vaccines and Related Biological 
Products Advisory Committee briefing document. Meeting date: 10 December 2020. Food and Drug 
Administration; 2020 (www.fda.gov/media/144246/download, accessed 10 December 2020).   
(2)  Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S et al. Phase I/II study of 
COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020;586(7830):589-93. 
(3)  Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S et al. Safety and efficacy of the 
BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020: 383:2603-2615.. 
  
 
a For the risk of bias assessments using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), please see 
www.covid-nma.com/vaccines. 
b Downgraded for limitations in follow-up time of clinical trial, which may not allow detection of adverse events occurring 
several months after vaccination. Not adequately powered to detect rare adverse events. These may emerge only when large 
populations have been vaccinated. 
Background document on the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19 
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Annex 5: GRADE table: Efficacy of BNT162b2 COVID-19 vaccine in individuals with underlying 
conditions 
Population: Individuals with comorbidities or health states that increase risk for severe COVID-19 
Intervention: Two doses of BNT162b2 vaccine 
Comparison: Placebo/ no vaccination 
Outcome: COVID-19 (PCR-confirmed) 
What is the efficacy of two doses of BNT162b2 vaccine compared with placebo in preventing PCR-confirmed 
COVID-19 in individuals with comorbidities or health states that increase risk for severe COVID-19? 
    Rating Adjustment to rating 
   















Limitation in study 
designa Not serious 0 
Inconsistency Not serious 0 
Indirectness Seriousb,c  -1 
Imprecision Not serious 0 




Large effect Not applicable  0 
Dose-response Not applicable  0  
Antagonistic bias 
and confounding Not applicable  0  












Statement on quality of evidence 
Evidence supports a moderate level of confidence 
that the true effect lies close to that of the estimate 
of the effect on the health outcome (level 3, or 
⊕⊕⊕). 
Conclusion 
We are moderately confident that 2 doses of 
BNT162b2 vaccine are efficacious in preventing 
PCR-confirmed COVID-19 in individuals with 
comorbidities or health states that increase risk for 
severe COVID-19 as included in the clinical trial. 
No data were obtained on vaccination of pregnant 
or breastfeeding women, or persons who were 
immunocompromised. 
References: 
(1)  Pfizer-BioNtech COVID-19 vaccine (Bnt162, Pf-07302048). Vaccines and Related Biological 
Products Advisory Committee briefing document. Meeting date: 10 December 2020. Food and Drug 
Administration; 2020 (www.fda.gov/media/144246/download, accessed 10 December 2020).   
(2)  Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S et al. Safety and efficacy of the 
BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020: 383:2603-2615..  
 
a For the risk of bias assessments using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), please see 
www.covid-nma.com/vaccines. 
b Around 46% of the trial population were either obese or affected by co-morbidities. Data on long-term protection emerging 
from the ongoing phase 2/3 clinical trial remain limited, as trial data have so far been reported only for a follow-up of 
approximately 2 months. This was considered as not constituting a limitation that would lead to downgrading of the 
evidence. SAGE will continue to review any emerging data and adjust its quality assessment as required. 
c Trial excluded pregnant and breastfeeding women, and persons who were immunocompromised.  
Background document on the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19 
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Annex 6: GRADE table: Safety of BNT162b2 COVID-19 vaccine in individuals with underlying conditions 
Population: Individuals with comorbidities or health states that increase risk for severe COVID-19 
Intervention: One or two doses of BNT162b2 vaccine 
Comparison: Placebo/ no vaccination 
Outcome: Serious adverse events following immunization 
What is the risk of serious adverse events following BNT162b2 vaccination compared with placebo in individuals 
with comorbidities or health states that increase risk for severe COVID-19? 
    Rating Adjustment to rating 
   















Limitation in study 
designa Serious
b -1 
Inconsistency Not serious 0 
Indirectness Seriousc -1 
Imprecision Not serious 0 




Large effect Not applicable  0 
Dose-response Not applicable  0  
Antagonistic bias 
and confounding Not applicable  0  












Statement on quality of evidence 
Evidence supports a limited level of confidence 
that the true effect lies close to 
that of the estimate of the effect on the health 
outcome (level 2, or ⊕⊕). 
Conclusion 
We have low confidence in the quality of evidence 
that the risk of serious adverse events in 
individuals with comorbidities or health states that 
increase risk for severe COVID-19 following one 
or two doses of BNT162b2 vaccine COVID-19 is 
low. 
References: 
(1)  Pfizer-BioNtech COVID-19 vaccine (Bnt162, Pf-07302048). Vaccines and Related Biological 
Products Advisory Committee briefing document. Meeting date: 10 December 2020. Food and Drug 
Administration; 2020 (www.fda.gov/media/144246/download, accessed 10 December 2020).    
(2)  Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S et al. Safety and efficacy of the 
BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020: 383:2603-2615.. 
 
a For the risk of bias assessments using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), please see 
www.covid-nma.com/vaccines. 
b Downgraded for limitations in follow-up time of clinical trial, which may not allow detection of adverse events occurring 
several months after vaccination. Not adequately powered to detect rare adverse events. These may emerge only when large 
populations have been vaccinated. 
c Trial excluded pregnant and breastfeeding women, and persons who were immunocompromised.  




Annex 7: SAGE evidence-to-recommendation framework: BNT162b2 mRNA vaccine use in adults 
 
Question: Should BNT162b2 mRNA vaccine be administered to adults to prevent COVID-19?  
Population: Adults (16–55 years) 
Intervention:  Two doses of BNT162b2 vaccine 
Comparison(s): No vaccination/placebo 
Outcome: COVID-19 (PCR-confirmed) 
Background:  On 31 December 2019, WHO was alerted to several cases of pneumonia of unknown origin in Wuhan City, Hubei Province, China. The cause 
was found to be a novel coronavirus, SARS-CoV-2. The disease caused by this novel virus has been named COVID-19. The outbreak of COVID-19 was 
declared a public health emergency of international concern in January 2020. The disease has since spread, with an enormous impact on the health and well-
being of individuals and populations worldwide. It has further caused major disruptions to various sectors of society and the economy across the globe. 
















The cumulative number of COVID-19 cases 
globally has surpassed 70 228 447, with more 
than 1 595 000 deaths. Cases have been found 
in 190 different countries or territories 
throughout the world (status 13 Dec 2020). 
There has been collateral damage to other 
public health programmes. 
The COVID-19 situation is 
evolving rapidly; the most recent 
epidemiological situation can be 
found on the following website: 
https://covid19.who.int/table 




























No Un-certain Yes 
Varie
s 
Primary efficacy analysis shows that BNT162b2 
is 95.6%  efficacious (95%CI: 89.4–98.6%) in 
individuals aged 16–55 years against COVID-




Phase 1/2 trial data (3) show  
immunogenicity of the BTNT162b1 
vaccine, receptor-binding domain 
(RBD)-binding IgG concentrations 
and SARS-CoV-2 neutralizing titres 
in sera increased with dose level 
(10, 30 and 100 μg) and after a 
second dose. Geometric mean 
☐ ☐ ☒ ☐ 






neutralizing titres reached 1.9-4.6-
fold that of a panel of COVID-19 
convalescent human sera. 
Further, two doses of 1–50 μg of 
BNT162b1 elicited robust CD4+ 
and CD8+ T-cell responses (4). 
Vaccine candidate BTNT162b2 
elicited similar dose-dependent 
SARS-CoV-2–neutralizing 
geometric mean titres as did 
candidate BTNT162b1 (5). 






effects small?  
No Un-certain Yes 
Varie
s  
Data from over 37 586 participants demonstrate 
that BNT162b2 vaccine was well tolerated 
across all populations. Systemic events were 
reported more often by younger vaccine 
recipients (16–55 years of age) than by older 
vaccine recipients (>55 
years of age) and more often after dose 2 than 
dose 1.  Few participants in either group had 
severe adverse events, serious adverse events, or 
adverse events leading to withdrawal from the 
trial. Four related serious adverse events were 
reported among BNT162b2 recipients (shoulder 
injury related to vaccine administration, right 
axillary lymphadenopathy, paroxysmal 
ventricular arrhythmia, and right leg 
paresthesia).  
There are no long-term safety data available yet 
and follow-up time remains limited. 
After country implementation of vaccination  in 
the United Kingdom and the USA, cases of 
anaphylactic reactions to the vaccine were 
observed in people with and without a history of 
severe allergic reactions to other antigens (6).  
Local reactions and systemic events 
reported after administration of the 
BNT162b1 vaccine were dose-
dependent (3). BNT162b2 was 
associated with a lower incidence 
and severity of systemic reactions 
than BNT162b1, hence chosen for 
evaluation in phase 2/3 clinical 
trials (5). 
☐ ☒ ☐ ☐ 



























Efficacy data suggest benefit, and short-term 
safety data suggest minimal harms. Further 
ongoing studies will need to be undertaken as 
part of post-marketing surveillance. 
 
☒ ☐ ☐ ☐ ☐ 
What is the 
overall quality 
of this evidence 
for the critical 
outcomes? 








Low Mod-erate High 
☐ ☐ ☐ ☐ ☒ 








Low Mod-erate High 































































Available scientific evidence on the relative 
importance of the intervention, as well as the 
relative weights that the target population 
attributes to the desirable (i.e. protection 
conferred by the vaccine) and the undesirable 
outcomes (i.e. the currently reported safety 
signals), vary.  
There may also be variability around novel 
product platforms for mRNA vaccines, which 
may represent a source of 
uncertainty/variability. 
Different population groups may have different 
opinions regarding the weights assigned to 
desirable and undesirable outcomes.  
 
☐ ☒ ☐ ☐ ☐ 





























Available scientific evidence suggests that 
target population probably assigns more weight 
to the desirable effects than to the undesirable 
effects related to COVID-19 vaccination. 
Targeted information campaigns should assess 
this aspect. 
 














No Un-certain Yes 
Varie
s  
Considerable resources will be needed to ensure 
the implementation of a COVID-19 vaccination 
programme, especially given: (i) that COVID-
19 vaccination is likely to be prioritized for 
populations (e.g. health care workers, older 
adults) without pre-existing robust 
immunization programmes in many settings, 
and (ii) the urgency of vaccination roll-out 
worldwide, which may necessitate additional 
surge resources to accelerate implementation 
with adequate infection prevention and control 
procedures in the context of COVID-19. 
Resources required include, but are not 
restricted to, human resources, vaccine costs, 
logistics, cold-chain capacity, planning and 
coordination, training, social mobilization and 
communications, and immunization safety 
surveillance.  
An estimated US$15.9 billion is 
needed for the vaccines pillar 
(COVAX) of the Access to COVID-
19 Tools Accelerator (ACT-A) for 
2020–21, when the initiative aims to 
deliver 2 billion doses. This does 
not include all delivery costs in all 
countries participating in COVAX, 
bilateral procurement deals, or 
research and development 
investments outside of COVAX (7). 
The World Bank has approved a 
financing window of up to US$12 
billion to support low- and middle-
income countries in purchasing and 
distributing vaccine (8). 
☒ ☐ ☐ ☐ 
Cost-
effectiveness 
No Un-certain Yes 
Varie
s 
Formal global cost-effectiveness analyses 
have not been conducted, but the emerging 
evidence indicates that the benefits, including 
the impact on recovery of the global economy, 
are likely to outweigh the cost of COVID-19 
The global economy is estimated to 
be losing US$375 billion per month 
due to the coronavirus pandemic. 
G20 countries have invested 
approximately US$10 trillion in 
domestic economic stimulus to 




☐ ☐ ☐ ☒ 
vaccination. Cost-effectiveness analyses should 
be conducted at country level; cost-
effectiveness of COVID-19 vaccination may 
vary by country depending on COVID-19 
burden, comparator interventions assessed, 
analysis perspective, and local cost-
effectiveness thresholds used. 
mitigate the economic consequences 
of reduced business activity and 







What would be 









Equity and ethical considerations are critical. 
SAGE has produced a Values Framework (15), 
which offers guidance on the fair allocation of 
COVID-19 vaccines based on six core ethical 
principles that should guide distribution. If 
distributed fairly, COVID-19 vaccines may 
have considerable impact on reducing health 
inequities.   
The ultra-low-temperature storage requirements 
of the current formulation of the Pfizer vaccine 
raise equity concerns, both within countries and 
globally. Ultracold chain capacity is not 
currently available in many low- and middle-
income-countries, and in some regions of high-
income countries, particularly in hard-to-reach 
or otherwise already disadvantaged 
communities. If other vaccines with less 
demanding storage requirements are not made 
available, or if vaccines that are feasible and 
available to deliver are less efficacious or less 
safe, health inequities will result and existing 
health inequities may be exacerbated.  
Vaccine nationalism is seen as a 
threat to reducing health inequity, in 
particular as high-income countries 
have arranged bilateral contracts 
with manufacturers. This has led to 
the establishment of the  Access to 
COVID-19 Tools (ACT) 
Accelerator and within this, the 
COVAX facility, which aims to 
ensure equitable access to vaccines 
for its participating member states 
(16). 


























No scientific evidence is available. As 
vaccination is an eagerly awaited tool to combat 
COVID-19, it is assumed that key stakeholders, 
in particular ministries of health and 
immunization managers, are strongly in favour 
of it. But they may need to convince other 
The fact that 190 economies are 
participating in COVAX suggests a 
very high acceptability of COVID-
19 vaccination in general, though 
not necessarily of this vaccine in 
particular.   




☒ ☐ ☐ ☐ ☐ 
partners or stakeholders to support COVID-19 
immunization. 












Vaccine acceptability varies between (sub-) 
population groups and may be correlated with 
the perceived risk posed by the disease. In a 
global survey (19 countries) of acceptance rates 
in the general population of any COVID-19 
vaccine product, 71.5% of participants reported 
that they would be very or somewhat likely to 
take a COVID-19 vaccine. Acceptance rates 
ranged from almost 55% to 87% (17). 
 































BNT162b2 is an ultra-low-temperature 
formulation and needs to be stored at –70 °C. 
Ultracold chain may not be available, in 
particular in low- and middle-income-countries, 
and is expensive and time-consuming to 
establish.  
BNT162b2 vaccine is not provided with a 
diluent, which needs to be procured separately 
by national programmes.   
The combination of the product’s 
logistic features and its 
reactogenicity makes mass 
workplace vaccination, which will 
be intended for this vaccine in many 
settings, more difficult. In 
particular, if many health workers 
are vaccinated at the same time, 
several may be unable to work the 
next day because of mild post-
vaccination immune responses.   
☐ ☐ ☐ ☐ ☐ ☒ 












consequences in most 
settings 
The balance between desirable 
and undesirable consequences 










consequences in most 
settings 




☐ ☐ ☐ ☐ ☒ 
Type of recommendation 
We recommend 
the intervention 
We suggest considering recommendation of the 
intervention 
We recommend the 
comparison 
We recommend against 
the intervention and the 
comparison 
☐ ☐ Only in the context of rigorous research  ☐ 
 
☐ 
 ☒ Only with targeted monitoring and evaluation 
☐ Only in specific contexts or specific (sub)populations 
Recommendation (text) 
Vaccination with BNT162b2 is recommended in persons aged 16 and above. The recommended schedule is two doses (30 µg, 0.3 
ml each) given intramuscularly into the deltoid muscle. An interval of 21–28 days between the doses is recommended. If the second 
dose is inadvertently administered less than 21 days after the first, the dose does not need to be repeated. If administration of the 
second dose is inadvertently delayed it should be given as soon as possible thereafter, according to the manufacturer’s instructions. 
It is currently recommended that individuals receive no more than two doses in total. 
Implementation 
considerations 
Before implementation, countries should consider whether they have adequate logistic and ultracold-chain capacity in place to 
ensure vaccine distribution and administration under the mentioned requirements. In countries where various immunization 
stakeholders have a crucial role in vaccine distribution, information and open discussion will be required before the vaccine is 
deployed. 




Monitoring and evaluation 
WHO recommends the following post-authorization monitoring activities: 
• vaccine effectiveness over time; 
•  ongoing collection of safety data in vaccine recipients; 
• surveillance for COVID-19 among vaccinated individuals, looking for vaccine-induced enhanced disease (possibly as 
vaccine-induced antibody levels decline); 
• safety data from inadvertently vaccinated pregnant women during trials and post-authorization; 
• safety data from pregnant women who receive vaccine because they are members of prioritized groups, e.g. health workers; 
• prospective studies on the safety of BNT162b2 in pregnant women; 
• impact on infants of vaccination of breastfeeding mothers; 
• safety data on vaccination in immunocompromised persons, including persons living with HIV and persons with autoimmune 
disease; 
• impact of delayed second dose as currently implemented by certain countries. 
Research priorities 
WHO recommends the following research activities:  
• clinical trials on the efficacy and safety of vaccination of children below the age of 16 years; 
• immunogenicity and safety studies of co-administration with other vaccines, including influenza and pneumococcal 
vaccines, to adults and older persons; 
• studies to determine how protection changes with time since vaccination and whether protection can be prolonged by booster 
doses; 
• studies to demonstrate whether this vaccine reduces SARS-CoV-2 transmission and viral shedding; 
• stability of vaccine under alternative cold-chain distribution and storage conditions; 
• effectiveness of the proposed strategies for the prevention and management of anaphylactic reactions; 
• interchangeability and “mix and match” studies within and across COVID-19 vaccine platforms; 
• global surveillance of virus evolution and the impact of virus mutants on vaccine effectiveness to support possible update of 
vaccines if needed; 
• head-to-head studies with other vaccines on extent and duration of immunity using standardized neutralization assays and 
mucosal immunity assays.  
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Annex 8: SAGE evidence-to-recommendation framework: BNT162b2 mRNA vaccine use in older adults 
 
Question: Should BNT162b2 mRNA vaccine be administered to older adults to prevent COVID-19?  
Population: Older adults (>55 years) 
Intervention:  Two doses of BNT162b2 vaccine 
Comparison(s): No vaccination/Placebo 
Outcome: COVID-19 (PCR-confirmed) 
Background:  On 31 December 2019, WHO was alerted to several cases of pneumonia of unknown origin in Wuhan City, Hubei Province, China. The cause 
was found to be a novel coronavirus, SARS-CoV-2. The disease caused by this novel virus has been named COVID-19. The outbreak of COVID-19 was 
declared a public health emergency of international concern in January 2020. The disease has since spread with an enormous impact on the health and well-being 
of individuals and populations worldwide. It has further caused major disruptions to various sectors of society and the economy across the globe. 
















The cumulative number of COVID-19 cases 
globally has surpassed 70 228 447 with more 
than 1 595 000 deaths. Cases have been  found 
in 190 different countries or territories 
throughout the world (status 13 December 
2020). There has been collateral damage to 
other public health programmes. 
Older adults are particularly affected by 
COVID-19 and bear a significantly higher risk 
of severe COVID-19 outcomes and death. 
The COVID-19 situation is 
evolving rapidly; the most recent 
epidemiological situation can be 
found on the following website: 
https://covid19.who.int/table 




























No Un-certain Yes 
Varie
s 
Primary efficacy analysis shows that BNT162b2 
is 93.7% efficacious (95%CI: 80.6–98.8%) in 
individuals aged >55 years, 94.7% (95%CI: 
66.7–99.9%) in those ≥65 years and  100.0% 
(95%CI: −13.1–100.0%) in those ≥75 years 
beginning 7 days after the second dose.(1;2)  
Of the trial participants, approximately 40% 
were aged 55 years or older. 
Phase 1/2 trial data (3) show  
immunogenicity of the BNT162b1 
vaccine, receptor-binding domain 
(RBD)-binding IgG concentrations 
and SARS-CoV-2 neutralizing titres 
in sera increased with dose level 
(10, 30 and 100 μg) and after a 
second dose using the same 
☐ ☐ ☒ ☐ 






concentration. Geometric mean 
neutralizing titres reached 1.9-4.6-
fold compared with that of a panel 
of COVID-19 convalescent human 
sera. 
Further, two doses of 1-50 μg of 
BNT162b1 elicited robust CD4+ 
and CD8+ T cell responses (4). 
Vaccine candidate BNT162b2 
elicited similar dose-dependent 
SARS-CoV-2–neutralizing 
geometric mean titres as did 
candidate BNT162b1 (5). 
 






effects small?  
No Un-certain Yes 
Varie
s  
Data from over 37 586 participants demonstrate 
that BNT162b2 vaccine was well tolerated. 
Systemic events were reported more often by 
younger vaccine recipients (16–55 years of age) 
than by older vaccine recipients (>55 years of 
age) and more often after dose 2 than dose 1. 
Few participants in either group had severe 
adverse events, serious adverse events, or 
adverse events leading to withdrawal from the 
trial. Four related serious adverse events were 
reported among BNT162b2 recipients (shoulder 
injury related to vaccine administration, right 
axillary lymphadenopathy, paroxysmal 
ventricular arrhythmia, and right leg 
paresthesia).  
There are no long-term safety data available yet 
and the follow-up time remains limited. 
After country implementation of vaccination in 
the United Kingdom and the USA, cases of 
anaphylactic reactions to the vaccine were 
observed in people with and without a history of 
severe allergic reactions to other antigens (6). 
Local reactions and systemic events 
reported after administration of the 
BNT162b1 vaccine were dose-
dependent (3). BNT162b2 was 
associated with a lower incidence 
and severity of systemic reactions 
than BNT162b1, and was chosen 
for evaluation in phase 2/3 clinical 
trials (5). 
☐ ☒ ☐ ☐ 




























Efficacy data suggest benefit, and short-term 
safety data suggest minimal harm. Further 
ongoing studies will need to be undertaken as 
part of post-marketing surveillance. 
 
☒ ☐ ☐ ☐ ☐ 
What is the 
overall quality 
of this evidence 
for the critical 
outcomes? 








Low Mod-erate High 
☐ ☐ ☐ ☐ ☒ 
 
 








Low Mod-erate High 


























































The majority of severe disease occurs in older 
individuals. Available scientific evidence 
suggests that the target population probably 
considers the desirable effects, i.e. the 
protection conferred by the vaccine, more 
important than the undesirable effects, i.e. the 













bility There may also be variability around novel product platforms for mRNA vaccines, which 
may represent a source of 
uncertainty/variability. 
Different population groups may have different 
opinions regarding the weights assigned to 






























Available scientific evidence suggests that the 
target population probably assigns more weight 
to the desirable effects than the undesirable 
effects related to COVID-19 vaccination. 
Targeted information campaigns should assess 
this aspect. 
 














No Un-certain Yes 
Varie
s  
Considerable resources will be needed to ensure 
the implementation of a COVID-19 vaccination 
programme, especially given: (i) that COVID-
19 vaccination is likely to be prioritized for 
populations (e.g. health care workers, older 
adults) without pre-existing robust 
immunization programmes in many settings, 
and (ii) the urgency of vaccination roll-out 
worldwide, which may necessitate additional 
surge resources to accelerate implementation 
with adequate infection prevention and control 
procedures in the context of COVID-19. 
Resources required include, but are not 
restricted to human resources, vaccine costs, 
logistics, cold-chain capacity, planning and 
coordination, training, social mobilization and 
communications, and immunization safety 
surveillance. 
An estimated US$15.9 billion is 
needed for the vaccines pillar 
(COVAX) of the Access to COVID-
19 Tools Accelerator (ACT-A) for 
2020–21, when the initiative aims to 
deliver 2 billion doses. This does 
not include all delivery costs in all 
countries participating in COVAX, 
bilateral procurement deals, or 
research and development 
investments outside of COVAX (7). 
The World Bank has approved a 
financing window of up to US $12 
billion to support low- and middle-
income countries in purchasing and 
distributing vaccine (8). 







Formal global cost-effectiveness analyses have 
not been conducted, but the emerging evidence 
The global economy is estimated to 
be losing US$375 billion per month 




☐ ☐ ☐ ☒ 
indicates that the benefits, including the impact 
on recovery of the global economy are likely to 
outweigh the cost of COVID-19 vaccination. 
Cost-effectiveness analyses should be 
conducted at country level; cost-effectiveness of 
COVID-19 vaccination may vary by country 
depending on COVID-19 burden, comparator 
interventions assessed, analysis perspective, and 
local cost-effectiveness thresholds used. 
due to the coronavirus pandemic.  
G20 countries have invested 
approximately US$10 trillion in 
domestic economic stimulus to 
mitigate the economic consequences 
of reduced business activity and 







What would be 









Equity and ethical considerations are critical. 
SAGE has produced a Values Framework (15), 
which offers guidance on the fair allocation of 
COVID-19 vaccines based on six core ethical 
principles that should guide distribution. If they 
are distributed fairly. COVID-19 vaccines may 
have considerable impact on reducing health 
inequities.   
The ultra-low-temperature storage requirements 
of the current formulation of the Pfizer vaccine 
raise equity concerns, both within countries and 
globally. Ultracold chain capacity is not 
currently available in many low- and middle-
income-countries, and in some regions of high-
income countries, particularly in hard to reach 
or otherwise already disadvantaged 
communities. If other vaccines with less 
demanding storage requirements are not made 
available, or if vaccines that are feasible and 
available to deliver are less efficacious or less 
safe, health inequities will result and existing 
health inequities may be exacerbated.  
Vaccine nationalism is seen as a 
threat to reducing health inequity, in 
particular as high-income countries 
have arranged bilateral contracts 
with manufacturers. This has led to 
the establishment of the  Access to 
COVID-19 Tools (ACT) 
Accelerator and, within this, the 
COVAX facility, which aims to 
ensure equitable access to vaccines 
for its participating member states 
(16). 
☒ ☐ ☐ ☐ 






























No scientific evidence is available. As 
vaccination is an eagerly awaited tool to combat 
COVID-19, it is assumed that key stakeholders, 
in particular ministries of health and 
immunization managers are strongly in favour 
of COVID-19 vaccination. 
But they may need to convince other partners or 
stakeholders to support COVID-19 
immunization. 
The fact that 190 economies are 
participating in COVAX suggests a 
very high acceptability of COVID-
19 vaccination in general, though 
not necessarily of this vaccine in 
particular.   
☒ ☐ ☐ ☐ ☐ 












Vaccine acceptability varies between (sub-) 
population groups, and may be correlated with 
the perceived risk posed by the disease. In a 
global survey (19 countries) of acceptance rates 
in the general population of any COVID-19 
vaccine product, 71.5% of participants reported 
that they would be very or somewhat likely to 
take a COVID-19 vaccine. Acceptance rates 
ranged from almost 55% to 87% (17). 
 































BNT162b2 is an ultra-low temperature 
formulation and needs to be stored at –70 °C. 
Ultracold chain may not be available, in 
particular in low- and middle-income-countries, 
and is expensive and time-consuming to 
establish. BNT162b2 vaccine is not provided 
with a diluent: this needs to be procured 
separately by national programmes.   
 
☐ ☐ ☐ ☐ ☐ ☒ 











in most settings 
Undesirable 
consequences 
probably outweigh  
desirable 
consequences 
in most settings 
The balance between  
desirable and undesirable 
consequences  
is closely balanced or 
uncertain 
Desirable consequences  
probably outweigh  
undesirable 
consequences 
in most settings 
Desirable consequences  
clearly outweigh  
undesirable 
consequences 
in most settings 
☐ ☐ ☐ ☐ ☒ 
Type of recommendation 
We recommend 
the intervention 
We suggest considering recommendation of the 
intervention 
We recommend the 
comparison 
We recommend against 
the intervention and the 
comparison 
☐ ☐ Only in the context of rigorous research  ☐ 
 
☐ 
 ☒ Only with targeted monitoring and evaluation 
☐ Only in specific contexts or specific (sub)populations 
Recommendation (text) 
The risk of severe COVID-19 and death increases steeply with age. Data from the phase 3 trial indicate that the efficacy and safety 
of the vaccine are comparable across all age groups (above the age of 16). Vaccination is recommended for older persons. Persons 
above the age of 85 years and very frail older persons were not included in the clinical trials. However, the safety and 
immunogenicity data obtained in a large subset of older people with and without comorbidities suggest that the benefits of 
vaccination outweigh the potential risks. Vaccination is recommended for older persons without an upper age limit. 
Implementation 
considerations 
Before implementation, countries should consider whether they have adequate logistic and ultracold-chain capacity in place to 
ensure vaccine distribution and administration under the mentioned requirements. In the countries where various immunization 
stakeholders have a crucial role in vaccine distribution, information and open discussion will be required before the vaccine is 
deployed. 




Monitoring and evaluation 
WHO recommends the following post-authorization monitoring activities: 
• vaccine effectiveness over time; 
• ongoing collection of safety data in vaccine recipients; 
• surveillance for COVID-19 among vaccinated individuals, looking for vaccine-induced enhanced disease (possibly as 
vaccine-induced antibody levels decline); 
• safety data from inadvertently vaccinated pregnant women during trials and post-authorization; 
• safety data from pregnant women who receive vaccine because they are members of prioritized groups, e.g. health workers; 
• prospective studies on the safety of BNT162b2 in pregnant women; 
• impact on infants of vaccination of breastfeeding mothers; 
• safety data on vaccination in immunocompromised persons, including persons living with HIV and persons with autoimmune 
disease; 
• impact of delayed second dose as currently implemented by certain countries. 
Research priorities 
WHO recommends the following research activities:  
• clinical trials on the efficacy and safety of vaccination of children below the age of 16 years; 
• immunogenicity and safety studies of co-administration with other vaccines, including influenza and pneumococcal 
vaccines, to adults and older persons; 
• studies to determine how protection changes with time since vaccination and whether protection can be prolonged by booster 
doses; 
• studies to demonstrate whether this vaccine reduces SARS-CoV-2 transmission and viral shedding; 
• stability of vaccine under alternative cold-chain distribution and storage conditions; 
• effectiveness of the proposed strategies for the prevention and management of anaphylactic reactions; 
• interchangeability and “mix and match” studies within and across COVID-19 vaccine platforms; 
• global surveillance of virus evolution and the impact of virus mutants on vaccine effectiveness to support possible update of 
vaccines if needed; 
• head-to-head studies with other vaccines on extent and duration of immunity using standardized neutralization assays and 
mucosal immunity assays.  
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Annex 9: SAGE evidence-to-recommendation framework: BNT162b2 mRNA vaccine use in individuals with comorbidities 
Question: Should BNT162b2 mRNA vaccine be administered to individuals with comorbidities or health states that increase risk for severe COVID-1915 to 
prevent COVID-19?   
Population: Individuals with comorbidities or health states that increase risk for severe COVID-19 
Intervention:  Two doses of BNT162b2 vaccine 
Comparison(s): No vaccination/Placebo 
Outcome: COVID-19 (PCR-confirmed) 
Background:  On 31 December 2019, WHO was alerted to several cases of pneumonia of unknown origin in Wuhan City, Hubei Province, China. The cause 
was found to be a novel coronavirus, SARS-CoV-2. The disease caused by this novel virus has been named COVID-19. The outbreak of COVID-19 was 
declared a public health emergency of international concern in January 2020. The disease has since spread, with an enormous impact on the health and well-
being of individuals and populations worldwide. It has further caused major disruptions to various sectors of society and the economy across the globe. 







Is the problem a 
public health 





The cumulative number of COVID-19 cases 
globally has surpassed 70 228 447 with more 
than 1 595 000 deaths. Cases have been found 
in 190 countries or territories throughout the 
world (Status 13 Dec 2020). There has been 
collateral damage to other public health 
programmes. 
Individuals with certain comorbidities are 
particularly affected by COVID-19 and bear a 
higher risk of severe COVID-19 outcomes and 
death. Identified risk factors include 
comorbidities such as hypertension, chronic 
cardiac disease, non-asthmatic chronic 
pulmonary disease, chronic kidney disease, liver 
disease and obesity (particularly a body mass 
index (BMI) >40). People with multiple 
The COVID-19 situation is 
evolving rapidly; the most recent 
epidemiological situation can be 





☐ ☐ ☒ ☐ 
 
15 Medical and health conditions in individuals of any age, including the following: obesity, chronic conditions (e.g. hypertension, diabetes, asthma, pulmonary, liver, or kidney disease), chronic 
infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV) that is stable and controlled, any immunosuppression, pregnancy, organ transplant and 
cancer. 




comorbidities are at a higher risk of COVID-19-
related adverse outcomes (1). Although the 
relative risk may be high for some conditions, 
the absolute risk for younger adults with 
comorbidities is typically lower than for healthy 






























No Un-certain Yes 
Varie
s 
Primary efficacy analysis demonstrates that 
BNT162b2 is 95.6% efficacious (95%CI: 89.4–
98.6%) in individuals aged 16–55 years 
beginning 7 days after the second dose. Around 
46% of the trial population were either obese or 
affected by co-morbidities.  
Consistent vaccine efficacy was observed in 
subjects with a Charlson Comorbidity Index 
score of at least 1 or obesity. In those with any 
comorbidity or obesity, efficacy was 95.3% 
compared with 94.7% in those with no 
comorbidity, although these analyses were not 
adequately powered.  
Limited or no data are available on vaccination 




Phase 1/2 trial data (4) show    
immunogenicity of the BNT162b1 
vaccine, receptor-binding domain 
(RBD)-binding IgG concentrations 
and SARS-CoV-2 neutralizing titres 
in sera increased with dose level 
(10, 30 and 100 μg) and after a 
second dose. Geometric mean 
neutralizing titres reached 1.9–4.6-
fold that of a panel of COVID-19 
convalescent human sera. 
Further, two doses of 1–50 μg of 
BNT162b1 elicited robust CD4+ 
and CD8+ T cell responses (5). 
Vaccine candidate BNT162b2 
elicited similar dose-dependent 
SARS-CoV-2–neutralizing 
geometric mean titres as did 
candidate BNT162b1 (6). 
☐ ☐ ☒ ☐ 






effects small?  
No Un-certain Yes 
Varie
s  
Data from over 37 586 participants demonstrate 
that BNT162b2 vaccine was well tolerated 
Systemic events were reported more often by 
younger vaccine recipients (16–55 years of age) 
than by older vaccine recipients (more than 55 
years of age) and more often after dose 2 than 
dose 1.  Few participants in either group had 
severe adverse events, serious adverse events, or 
adverse events leading to withdrawal from the 
Local reactions and systemic events 
reported after administration of the 
BNT162b1 vaccine  were dose-
dependent.(4) BNT162b2 was 
associated with a lower incidence 
and severity of systemic reactions 
than BNT162b1, hence chosen for 
evaluation in Phase II/III clinical 
trials (6) 
☐ ☒ ☐ ☐ 




trial. Four related serious adverse events were 
reported among BNT162b2 recipients (shoulder 
injury related to vaccine administration, right 
axillary lymphadenopathy, paroxysmal 
ventricular arrhythmia, and right leg 
paresthesia).  
Limited or no data are available on vaccination 
of pregnant or severely immunosuppressed 
persons. 
After implementation of vaccination in the 
United Kingdom and the USA, cases of 
anaphylactic reactions to the vaccine were 
observed in people with and without a history of 
























Efficacy data suggest benefit, and the short-term 
safety data suggest minimal harms. Further 
studies will need to be undertaken as part of 
post-marketing surveillance. 
 
☒ ☐ ☐ ☐ ☐ 
What is the 
overall quality 
of this evidence 
for the critical 
outcomes? 








Low Mod-erate High 
☐ ☐ ☐ ☒ ☐ 








Low Mod-erate High 
☐ ☐ ☒ ☐ ☐ 


































































There is possibly important uncertainty related 
to the target population weighing of desirable 
and undesirable effects ( i.e. the protection 
conferred by the vaccine weighed against the 
currently reported safety signals, related to 
COVID-19 vaccination. 
There may also be variability around novel 
product platforms for mRNA vaccines, which 
may represent a source of 
uncertainty/variability. 
Different population groups may have different 
opinions regarding the relative weights 
attributed to desirable and undesirable outcomes 
 


























Available scientific evidence suggests that the 
target population probably attached more 
weight to the desirable effects than the 
undesirable effects related to COVID-19 
vaccination. 
Targeted information campaigns should assess 
this aspect. 
 














No Un-certain Yes 
Varie
s  
Considerable resources will be needed to ensure 
the implementation of a COVID-19 vaccination 
programme, especially given: (i) that COVID-
19 vaccination is likely to be prioritized for 
populations (e.g. health care workers, older 
adults) without pre-existing robust 
immunization programmes in many settings, 
and (ii) the urgency of vaccination roll-out 
worldwide, which may necessitate additional 
surge resources to accelerate implementation 
with adequate infection prevention and control 
procedures in the context of COVID-19. 
Resources required include, but are not 
An estimated US$15.9 billion is 
needed for the vaccines pillar 
(COVAX) of the Access to COVID-
19 Tools Accelerator (ACT-A) for 
2020–21, when the initiative aims to 
deliver 2 billion vaccine doses.  
This does not include all delivery 
costs in all countries participating in 
COVAX, bilateral procurement 
deals, or research and development 
investments outside of COVAX (8). 
☒ ☐ ☐ ☐ 




restricted to: human resources, vaccine costs, 
logistics, cold-chain capacity, planning and 
coordination, training, social mobilization and 
communications, and immunization safety 
surveillance. 
The World Bank has approved a 
financing window of up to US$12 
billion to support low- and middle-
income countries in purchasing and 







Formal global cost-effectiveness analyses have 
not been conducted, but the emerging evidence 
indicates that the benefits, including the impact 
on recovery of the global economy, are likely to 
outweigh the cost of COVID-19 vaccination. 
Cost-effectiveness analyses should be 
conducted at country level; cost-effectiveness of 
COVID-19 vaccination may vary by country 
depending on COVID-19 burden, comparator 
interventions assessed, analysis perspective, and 
local cost-effectiveness thresholds used. 
The global economy is estimated to 
be losing US$375 billion per month 
due to the coronavirus pandemic.  
G20 countries have invested 
approximately US$10 trillion in 
domestic economic stimulus to 
mitigate the economic consequences 
of reduced business activity and 
unemployment due to the pandemic 
(8, 10–15) 





 What would be 







Equity and ethical considerations are critical. 
SAGE has produced a Values Framework (16) 
Vaccine nationalism is seen as a 
threat to reducing health inequity, in 






☒ ☐ ☐ ☐ 
which offers guidance on the fair allocation of 
COVID-19 vaccines based on six core ethical 
principles that should guide distribution. If 
distributed fairly, COVID-19 vaccines may 
have considerable impact on reducing health 
inequities.   
The ultra-low-temperature storage requirements 
of the current formulation of the Pfizer vaccine 
raise equity concerns, both within countries and 
globally. Ultracold chain capacity is not 
currently available in many low- and middle-
income-countries, and in some regions of high-
income countries, particularly in hard-to-reach 
or otherwise already disadvantaged 
communities. If other vaccines with less 
demanding storage requirements are not made 
available, or if vaccines that are feasible and 
available to deliver are less efficacious or less 
safe, health inequities will result and existing 
health inequities may be exacerbated.  
particular as high-income countries 
have arranged bilateral contracts 
with manufacturers. This has led to 
the establishment of the  Access to 
COVID-19 Tools (ACT) 
Accelerator and, within this, the 
COVAX facility, which aims to 
ensure equitable access to vaccines 




























No scientific evidence is available. As 
vaccination is an eagerly awaited tool to combat 
COVID-19, it is assumed that key stakeholders, 
in particular ministries of health and 
immunization managers are strongly in favour 
of COVID-19 vaccination. 
But they may need to convince other partners or 
stakeholders to support COVID-19 
immunization.   
The fact that 190 economies are 
participating in  COVAX suggests a 
very high acceptability of COVID-
19 vaccination in general, though 
not necessarily of this vaccine in 
particular.   
☒ ☐ ☐ ☐ ☐ 












Vaccine acceptability varies between (sub-) 
population groups, and may be correlated with 
the perceived risk posed by the disease. In a 
global survey (19 countries) on acceptance rates 
 




☒ ☐ ☐ ☐ ☐ 
in the general population of any COVID-19 
vaccine product, 71.5% of participants reported 
that they would be very or somewhat likely to 
take a COVID-19 vaccine. Acceptance rates 































BNT162b2 is an ultra-low-temperature 
formulation and needs to be stored at –70 °C. 
Ultracold chain may not be available, in 
particular in low- and middle-income-countries, 
and is expensive and time-consuming to 
establish.  
BNT162b2 vaccine is not provided with a 
diluent, which needs to be procured separately 
by national programmes.   
 
☐ ☐ ☐ ☐ ☐ ☒ 












consequences in most 
settings 
The balance between desirable 
and undesirable consequences 










consequences in most 
settings 
☐ ☐ ☐ ☒ ☐ 
Type of recommendation 
We recommend 
the intervention 
We suggest considering recommendation of the 
intervention 
We recommend the 
comparison 
We recommend against 
the intervention and the 
comparison 
☐ ☐ Only in the context of rigorous research  ☐ ☐ 
☒ Only with targeted monitoring and evaluation 
☒ Only in specific contexts or specific (sub)populations 





Persons with comorbidities  
Certain comorbidities have been identified as increasing the risk of severe COVID-19 disease and death. Phase 2/3 clinical trials 
have demonstrated that the vaccine has similar safety and efficacy profiles in persons with various underlying medical conditions, 
including those that place them at increased risk for severe COVID-19. The comorbidities studied in phase 2/3 clinical trials include 
hypertension; diabetes; asthma; and pulmonary, liver and kidney disease; as well as chronic (stable and controlled) infection with 
human immunodeficiency virus (HIV), hepatitis C virus (HCV) and hepatitis B virus (HBV). Vaccination is recommended for 
persons with comorbidities that have been identified as increasing the risk of severe COVID-19.  
 
Immunocompromised persons 
Immunocompromised persons are at higher risk of severe COVID-19. Available data are currently insufficient to assess vaccine 
efficacy or vaccine-associated risks in severely immunocompromised persons. It is possible that the immune response to the 
vaccine may be reduced, which may alter its effectiveness. In the interim, given that the vaccine is not a live virus, 
immunocompromised persons who are part of a group recommended for vaccination may be vaccinated. Information and, where 
possible, counselling about vaccine safety and efficacy profiles in immunocompromised persons should be provided to inform 
individual benefit–risk assessment.  
 
Pregnant women 
Pregnant women are at higher risk of severe COVID-19 compared to women of child-bearing age who are not pregnant, and 
COVID19 has been associated with an increased risk of preterm birth. The available data on BNT162b2 vaccination of pregnant 
women are insufficient to assess vaccine efficacy or vaccine-associated risks in pregnancy. However, it should be noted that the 
BNT162b2 vaccine is not a live virus vaccine, the mRNA does not enter the nucleus of the cell and is degraded quickly. 
Developmental and reproductive toxicology (DART) studies in animals have not shown harmful effects in pregnancy. Further 
studies are planned in pregnant women in the coming months. As data from these studies become available, recommendations on 
vaccination will be updated accordingly. In the interim, WHO recommends not to use BNT162b2 in pregnancy, unless the benefit 
of vaccinating a pregnant woman outweighs the potential vaccine risks, such as in health workers at high risk of exposure and 
Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing: Interim 
guidance -4- pregnant women with comorbidities placing them in a high-risk group for severe COVID-19. Information and, if 
possible, counselling on the lack of safety and efficacy data for pregnant women should be provided. WHO does not recommend 
pregnancy testing prior to vaccination.  
 
Lactating women 
Breastfeeding offers substantial health benefits to lactating women and their breastfed children. Vaccine efficacy is expected to be 
similar in lactating women as in other adults. However, there are no data on the safety of COVID-19 vaccines in lactating women or 




on the effects of mRNA vaccines on breastfed children. As the BNT162b2 vaccine is not a live virus vaccine and the mRNA does 
not enter the nucleus of the cell and is degraded quickly, it is biologically and clinically unlikely to pose a risk to the breastfeeding 
child. On the basis of these considerations, a lactating woman who is part of a group recommended for vaccination, e.g. health 
workers, should be offered vaccination on an equivalent basis. WHO does not recommend discontinuing breastfeeding after 
vaccination.  
 
Persons living with HIV 
Persons living with HIV may be at higher risk of severe COVID-19. Among the phase 2/3 clinical trial participants with well 
controlled HIV, there were no reported differences in safety signals. HIV-positive persons who are well controlled on highly active 
antiretroviral therapy and are part of a group recommended for vaccination can be vaccinated. Available data on administration of 
the vaccine are currently insufficient to allow assessment of vaccine efficacy or safety for persons living with HIV who are not well 
controlled on therapy. It is possible that the immune response to the vaccine may be reduced, which may alter its effectiveness. In 
the interim, given that the vaccine is not a live virus, persons living with HIV who are part of a group recommended for vaccination 
may be vaccinated. Information and, where possible, counselling about vaccine safety and efficacy profiles in immunocompromised 
persons should be provided to inform individual benefit–risk assessment. It is not necessary to test for HIV infection prior to 
vaccine administration. 
 
Persons with autoimmune conditions  
No data are currently available on the safety and efficacy of BNT162b2 in persons with autoimmune conditions, although these 
persons were eligible for enrolment in the clinical trials. Persons with autoimmune conditions who have no contraindications to 
vaccination may be vaccinated.  
Implementation 
considerations 
Before implementation, countries should consider whether they have adequate logistic and ultracold-chain capacity in place to 
ensure vaccine distribution and administration under the mentioned requirements. In the countries where various immunization 
stakeholders have a crucial role in the vaccine distribution, information and open discussion will be required before the vaccine is 
deployed. 




Monitoring and evaluation 
WHO recommends the following post-authorization monitoring activities: 
• vaccine effectiveness over time; 
•  ongoing collection of safety data in vaccine recipients; 
• surveillance for COVID-19 among vaccinated individuals, looking for vaccine-induced enhanced disease (possibly as 
vaccine-induced antibody levels decline); 
• safety data from inadvertently vaccinated pregnant women during trials and post-authorization; 
• safety data from pregnant women who receive vaccine because they are members of prioritized groups, e.g. health workers; 
• prospective studies on the safety of BNT162b2 in pregnant women; 
• impact on infants of vaccination of breastfeeding mothers; 
• safety data on vaccination in immunocompromised persons, including persons living with HIV and persons with autoimmune 
disease; 
• impact of delayed second dose as currently implemented by certain countries. 
Research priorities 
WHO recommends the following research activities:  
• clinical trials on the efficacy and safety of vaccination of children below the age of 16 years; 
• immunogenicity and safety studies of co-administration with other vaccines, including influenza and pneumococcal 
vaccines, to adults and older persons; 
• studies to determine how protection changes with time since vaccination and whether protection can be prolonged by booster 
doses; 
• studies to demonstrate whether this vaccine reduces SARS-CoV-2 transmission and viral shedding; 
• stability of vaccine under alternative cold-chain distribution and storage conditions; 
• effectiveness of the proposed strategies for the prevention and management of anaphylactic reactions; 
• interchangeability and “mix and match” studies within and across COVID-19 vaccine platforms; 
• global surveillance of virus evolution and the impact of virus mutants on vaccine effectiveness to support possible update of 
vaccines if needed; 
• head-to-head studies with other vaccines on extent and duration of immunity using standardized neutralization assays and 
mucosal immunity assays.  
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